Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...1819202122232425262728...7475»
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Panretinal Photocoagulation for Diabetic Retinopathy in the RIDE and RISE Trials: Not "1 and Done". (Pubmed Central) -  Nov 25, 2021   
    P3
    In RIDE and RISE, PRP treatment was not a "1 and done" procedure, with on-study PRP re-treatment occurring in patients both with and without prior PRP treatment at baseline. Ranibizumab treatment reduced on-study PRP treatment and DR progression regardless of prior PRP treatment status at baseline.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Optical coherence tomography angiography in Tuberous sclerosis complicated with macular choroidal neovascularization. (Pubmed Central) -  Nov 25, 2021   
    This study describe the optical coherence tomography angiography (OCTA) features of a young patient with Tuberous sclerosis complicated with CNV unilateral macular choroidal neovascularization during the ranibizumab therapy...After four monthly intravitreal injections, OCTA revealed a decrease of size and activity of CNV. OCTA is a valid, non-invasive, dyeless, and reliable method that could improve the diagnosis and management of CNV in child with Tuberous sclerosis.
  • ||||||||||  Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron
    Clinical, Journal, HEOR:  Cost-Utility Analysis of Drug Treatments in Patients with Polypoidal Choroidal Vasculopathy in Thailand. (Pubmed Central) -  Nov 21, 2021   
    The combination of IVB or intravitreal ranibizumab (IVR) and verteporfin photodynamic therapy (IVB+vPDT or IVR+vPDT) yielded the highest quality-adjusted life-years (QALY)...None of the drug treatments for PCV was cost-effective in the Thai context. The decreased price of verteporfin is required to support the inclusion of IVB+vPDT in the Thai National List of Essential Medicines for the treatment of PCV.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Ultra-Response to Ranibizumab: Improvement by 4 or More Steps in Diabetic Retinopathy Severity in DRCR.net Protocol S. (Pubmed Central) -  Nov 21, 2021   
    The decreased price of verteporfin is required to support the inclusion of IVB+vPDT in the Thai National List of Essential Medicines for the treatment of PCV. Approximately 30% of eyes with an DRSS score of at least 47 receiving ranibizumab 0.5 mg per study protocol experienced at least 4-step DR severity improvement on the DRSS, accompanied by meaningful improvements in BCVA.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal:  Value of anti-VEGF Gene Therapy for Neovascular Age-Related Macular Degeneration. (Pubmed Central) -  Nov 21, 2021   
    This model can serve as a basis for assessing the price ceiling of myriad gene therapy approaches. Given the high present values for these therapeutics, innovative costing and reimbursement mechanisms should be further explored, with contingencies for sustained efficacy.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Expression of antibody fragments in Saccharomyces cerevisiae strains evolved for enhanced protein secretion. (Pubmed Central) -  Nov 21, 2021   
    These included the Fab fragment Ranibizumab (Ran), the scFv peptide Pexelizumab (Pex), and a nanobody consisting of a single V-type domain (Nan)...To investigate the mechanisms for different secretion abilities in these selected yeast strains for the different antibody fragments, RNA-seq analysis was performed. The results showed that several bioprocesses were significantly enriched for differentially expressed genes when comparing the enriched terms between HA.Nan vs. LA.Nan and HA.Pex vs. LA.Pex, including amino acid metabolism, protein synthesis, cell cycle and others, which indicates that there are unique physiological needs for each antibody fragment secretion.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Journal:  Factors Associated with Pain Level in Patients Receiving Intravitreal Injection. (Pubmed Central) -  Nov 17, 2021   
    The level of education, diagnosis, and active substance were found to have a statistically significant effect on pain perception. In this study, pain levels have been found to be high in smokers, those with a low educational level, individuals receiving bevacizumab for intravitreal injection, and those having a higher level of state anxiety, whereas patients with DR have lower pain scores.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron
    Retrospective data, Journal:  Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies. (Pubmed Central) -  Nov 17, 2021   
    In this study, pain levels have been found to be high in smokers, those with a low educational level, individuals receiving bevacizumab for intravitreal injection, and those having a higher level of state anxiety, whereas patients with DR have lower pain scores. This post hoc analysis provides additional evidence for the role of baseline CNV features (CNV type, total area, and leakage area) in influencing visual and anatomic outcomes in eyes with nAMD following anti-VEGF treatment.
  • ||||||||||  surabgene lomparvovec (ABBV-RGX-314) / REGENXBIO, AbbVie
    Enrollment change, Trial completion date, Trial primary completion date:  RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE) (clinicaltrials.gov) -  Nov 11, 2021   
    P2,  N=95, Recruiting, 
    This post hoc analysis provides additional evidence for the role of baseline CNV features (CNV type, total area, and leakage area) in influencing visual and anatomic outcomes in eyes with nAMD following anti-VEGF treatment. N=40 --> 95 | Trial completion date: Feb 2022 --> Jan 2023 | Trial primary completion date: Feb 2021 --> Jan 2022
  • ||||||||||  Susvimo (ranibizumab port delivery system) / Roche
    Journal:  Port Delivery System: A novel drug delivery platform to treat retinal diseases. (Pubmed Central) -  Nov 10, 2021   
    PDS may be able to substantially mitigate treatment burden while effectively generating visual and anatomic outcomes similar to those in patients receiving the gold standard of monthly ranibizumab for neovascular age-related macular degeneration. Further studies are ongoing to investigate the potential of this novel drug delivery system in other disease states.
  • ||||||||||  Triesence (triamcinolone acetonide injectable suspension) / Novartis, Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
    Enrollment open, Monotherapy:  Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (clinicaltrials.gov) -  Nov 9, 2021   
    P4,  N=150, Recruiting, 
    Further studies are ongoing to investigate the potential of this novel drug delivery system in other disease states. Not yet recruiting --> Recruiting
  • ||||||||||  moxifloxacin intravenous / Generic mfg.
    Journal:  The effect of topical ocular moxifloxacin on conjunctival and nasal mucosal flora. (Pubmed Central) -  Nov 4, 2021   
    All patients received intravitreal injection of ranibizumab...Patients were instructed to administer moxifloxacin eye drops to the treatment eye 4 times daily for 1 week...This is the first study to show that moxifloxacin applied to the ocular surface topically has a significant effect on nasal flora. Daily administration of topical ocular moxifloxacin for 1 week significantly reduces the nasal bacterial flora in addition to conjunctival flora.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  SURGICAL MANAGEMENT OF FULL-THICKNESS MACULAR HOLE SUPERIMPOSED ON EXUDATIVE AGE-RELATED MACULAR DEGENERATION. (Pubmed Central) -  Oct 31, 2021   
    Daily administration of topical ocular moxifloxacin for 1 week significantly reduces the nasal bacterial flora in addition to conjunctival flora. To the best of our knowledge, this is the first reported case of full-thickness macular hole after a retinal pigment epithelium tear repaired successfully with vitrectomy, resulting in improved visual acuity.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Intravitreal Aflibercept versus Ranibizumab for Diabetic Macular Edema in a Taiwanese Health Service Setting. (Pubmed Central) -  Oct 30, 2021   
    Both aflibercept and ranibizumab had similar rates of loss to follow-up (p = .47) and occurrence of vitreous hemorrhage (p = .21). While both agents improved vision with resolution of edema, aflibercept maintained vision more effectively with less recurrence of subretinal fluid at 12 months in real-world settings.
  • ||||||||||  Beovu (brolucizumab-dbll) / Novartis, Lucentis (ranibizumab) / Roche, Novartis, Xlucane (ranibizumab biosimilar) / Stada, Xbrane, Helvetic
    Journal, HEOR:  Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis. (Pubmed Central) -  Oct 28, 2021   
    Wykoff reports personal fees from Corcept Therapeutics, DORC, EyePoint, Gyroscope, IVERIC Bio, Merck, Notal Vision, ONL Therapeutics, Oxurion, Palatin, PolyPhotonix, Takeda, Thea Open Innovation; grants from Aerie Pharmaceuticals, Aldeyra, Gemini Therapeutics, Graybug Vision, IONIS Pharmaceutical, LMRI, Mylan, Neurotech Pharmaceuticals, Outlook Pharmaceuticals, Samsung Bioepis, Senju, Taiwan Liposome Company, Xbrane BioPharma, Santen; and grants and personal fees from Adverum, Allergan, Apellis, Chengdu Kanghong Biotechnologies (KHB), Clearside Biomedical, Genentech, Kodiak Sciences, NGM Biopharmaceuticals, Novartis, Opthea, Recens Medical, Regenxbio, Roche, and Regeneron, unrelated to this work. This research was presented as a virtual poster at the AMCP 2020 Annual Meeting, April 2020.
  • ||||||||||  Beovu (brolucizumab-dbll) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Review, Journal:  Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials. (Pubmed Central) -  Oct 28, 2021   
    One study reported no difference in the risk of macular atrophy between ranibizumab and aflibercept, whilst many studies have suggested that aflibercept causes more choroidal thinning, one of the risk factors for macular atrophy, than does ranibizumab. Further evaluation of drugs and regimens should be performed from the viewpoint of complications and minimum number of injections required to improve and maintain VA.
  • ||||||||||  GNR-067 (ranibizumab biosimilar) / Generium, Lucentis (ranibizumab) / Roche, Novartis
    Trial completion date, Trial initiation date, Trial primary completion date:  NAP: Efficacy, Safety, pharmacokineti?s, Immunogenicity of GNR-067 and Lucentis (clinicaltrials.gov) -  Oct 26, 2021   
    P3,  N=408, Not yet recruiting, 
    Our results might pave the way for additional exploration of these mechanisms. Trial completion date: Sep 2022 --> Sep 2024 | Initiation date: Mar 2021 --> Dec 2021 | Trial primary completion date: Aug 2022 --> Aug 2023
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Profiles of Cytokines Secreted by ARPE-19 Cells Exposed to Light and Incubated with Anti-VEGF Antibody. (Pubmed Central) -  Oct 25, 2021   
    In culture with aflibercept or ranibizumab in the dark, the levels of IL-6, IL-8, bFGF and MCP-1 were increased, and the IL-12 level decreased synchronously with a reduction in the VEGF-A level. Our findings indicate that continuous irradiation of visible light and VEGF suppression may be an influential factor in expression patterns of inflammatory cytokines secreted by human RPE cells.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Biomarker, Journal:  Anti-VEGF Drugs Influence Epigenetic Regulation and AMD-Specific Molecular Markers in ARPE-19 Cells. (Pubmed Central) -  Oct 22, 2021   
    Combination of bevacizumab plus TSA increased gene expression of SOD2, HIF-1α, GPX3A, BCL2L13, and CASPASE-3, and reduced CASPASE-9 and IL-β. In conclusion, we demonstrated that anti-VEGF drugs can: (1) alter expression of genes involved in oxidative stress (GPX3A and SOD2), inflammation (IL-18 and IL-1β) and apoptosis (BCL2L13, CASPASE-3, and CASPASE-9), and (2) TSA-induced deacetylation altered transcription for angiogenesis (HIF-1α), apoptosis, and inflammation genes.